← All Cg Oncology, INC filings

Cg Oncology, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CGON
Cg Oncology, INC
10-K: CG Oncology Advances Bladder Cancer Therapy with Strong Phase 3 Data
CG Oncology, Inc. reports promising Phase 3 clinical trial data for its lead product candidate, cretostimogene, in high-risk NMIBC, initiating BLA submission and expanding its bladder cancer pipeline.
NASDAQ
CGON
Cg Oncology, INC
10-K: CG Oncology Reports Promising Phase 3 Data, Eyes BLA Submission in 2025
CG Oncology's 10-K filing highlights positive clinical trial results for cretostimogene, positioning the company for a potential BLA submission in the second half of 2025.
NASDAQ
CGON
Cg Oncology, INC
10-K: CG Oncology Announces Positive Interim Phase 3 Results for Bladder Cancer Treatment, Plans for Further Expansion
CG Oncology, a late-stage clinical biopharmaceutical company, is advancing its bladder cancer therapeutic, cretostimogene, with promising interim Phase 3 trial results and plans for expanded clinical trials.